May 30, 2018
Via EDGAR Transmission
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Abigail Jacobs
Re: Verona Pharma plc
Registration Statement on Form F-3
Filed May 22, 2018
Registration No. 333-225107
Dear Ms. Jacobs:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on June 1, 2018 at 4:00 p.m. Eastern Time or as soon thereafter as practicable, or at such later time as Verona Pharma plc (the “Company”) or its counsel may request via telephone call to the staff. Please contact Peter Handrinos of Latham & Watkins LLP, counsel to the Company, at (617) 948-6060, or in his absence, Nathan Ajiashvili of Latham & Watkins LLP at (212) 906-2916, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
| Sincerely yours, | |
|
| |
| Verona Pharma plc | |
|
| |
| By: | /s/ Piers Morgan |
|
| Name: Piers Morgan |
|
| Title: Chief Financial Officer |
cc: Jan-Anders Karlsson, Verona Pharma plc
Claire Poll, Verona Pharma plc